ResearcherKarolinska University HospitalActive in the last 2 years
Mehran Ghaderi
Matched on ORCID iD 0000-0002-5396-6023; OpenAlex author ID A5033506960. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 9
2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 3 papers
Papers 7
- Se-methylselenocysteine induces NRF2-ATF4 stress signaling and ferroptosis-associated remodeling in pancreatic cancer. Co-author DOI 10.1016/j.freeradbiomed.2026.08.003↗
- Transcriptomic profiling reveals complement activation in chronic pancreatitis adjacent to pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.imbio.2026.153239↗
- Selenite modulates phenotype-dependent epithelial-mesenchymal plasticity in pancreatic ductal adenocarcinoma: integrated in vitro analyses and patient-derived … Co-author DOI 10.1186/s13046-026-03778-4↗
- Investigating the Molecular Impact of GGMSC on Redox and Metabolic Pathways in Pancreatic Cancer Cells. First author DOI 10.3390/antiox14101163↗
- Exploration of Patient-Derived Pancreatic Ductal Adenocarcinoma Ex Vivo Tissue for Treatment Response. Last author DOI 10.3390/antiox12010167↗
- Drug-induced tumor-specific cytotoxicity in a whole tissue ex vivo model of human pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2022.965182↗
- Genome-wide transcriptome profiling of ex-vivo precision-cut slices from human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-020-65911-3↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Joakim Dillner · 7 shared papers, 2020–2026 · strength 1.90
- Paper Se-methylselenocysteine induces NRF2-ATF4 stress signaling and ferroptosis-associated remodeling in pancreatic cancer. DOI 10.1016/j.freeradbiomed.2026.08.003↗
- Paper Transcriptomic profiling reveals complement activation in chronic pancreatitis adjacent to pancreatic ductal adenocarci… DOI 10.1016/j.imbio.2026.153239↗
- Paper Investigating the Molecular Impact of GGMSC on Redox and Metabolic Pathways in Pancreatic Cancer Cells. DOI 10.3390/antiox14101163↗
- Mikael Björnstedt · 7 shared papers, 2020–2026 · strength 1.90
- Paper Se-methylselenocysteine induces NRF2-ATF4 stress signaling and ferroptosis-associated remodeling in pancreatic cancer. DOI 10.1016/j.freeradbiomed.2026.08.003↗
- Paper Transcriptomic profiling reveals complement activation in chronic pancreatitis adjacent to pancreatic ductal adenocarci… DOI 10.1016/j.imbio.2026.153239↗
- Paper Investigating the Molecular Impact of GGMSC on Redox and Metabolic Pathways in Pancreatic Cancer Cells. DOI 10.3390/antiox14101163↗
- Arun Kumar Selvam · 5 shared papers, 2022–2026 · strength 1.45
- Paper Se-methylselenocysteine induces NRF2-ATF4 stress signaling and ferroptosis-associated remodeling in pancreatic cancer. DOI 10.1016/j.freeradbiomed.2026.08.003↗
- Paper Transcriptomic profiling reveals complement activation in chronic pancreatitis adjacent to pancreatic ductal adenocarci… DOI 10.1016/j.imbio.2026.153239↗
- Paper Investigating the Molecular Impact of GGMSC on Redox and Metabolic Pathways in Pancreatic Cancer Cells. DOI 10.3390/antiox14101163↗
- Carlos Fernández Moro · 5 shared papers, 2020–2026 · strength 1.14
- Paper Transcriptomic profiling reveals complement activation in chronic pancreatitis adjacent to pancreatic ductal adenocarci… DOI 10.1016/j.imbio.2026.153239↗
- Paper Selenite modulates phenotype-dependent epithelial-mesenchymal plasticity in pancreatic ductal adenocarcinoma: integrate… DOI 10.1186/s13046-026-03778-4↗
- Paper Exploration of Patient-Derived Pancreatic Ductal Adenocarcinoma Ex Vivo Tissue for Treatment Response. DOI 10.3390/antiox12010167↗
- Tímea Szekerczés · 2 shared papers, 2023–2026 · strength 0.52
- Ozan Aricak · 1 shared paper, 2026 · strength 0.32
- Béla Bozóky · 1 shared paper, 2022 · strength 0.16
- Marco Gerling · 1 shared paper, 2022 · strength 0.16
- Caroline Sophie Verbeke · 1 shared paper, 2020 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.